Get the Stockscreener App
0.721
1.11%
0.0079
After Hours:
.72
-0.001
-0.14%
Dare Bioscience Inc stock is traded at $0.721, with a volume of 437.46K.
It is up +1.11% in the last 24 hours and down -46.19% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$0.7131
Open:
$0.7
24h Volume:
437.46K
Relative Volume:
1.07
Market Cap:
$13.97M
Revenue:
$1.16M
Net Income/Loss:
$-12.02M
P/E Ratio:
-0.6945
EPS:
-1.0381
Net Cash Flow:
$-10.16M
1W Performance:
-1.90%
1M Performance:
-46.19%
6M Performance:
-53.78%
1Y Performance:
-66.15%
1-Day Range:
$0.70
$0.7573
1-Week Range:
$0.69
$0.82
52-Week Range:
$0.69
$3.78
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
0.721 | 15.68M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dare Bioscience Inc Stock (DARE) Latest News
Dare Bioscience, Inc. SEC Filing (Sep 4, 2026) - Stock Titan
Dare Bioscience Inc (DARE) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Dare Bioscience (DARE) Secures $908K NIH Grant Amidst Challengin - GuruFocus
Daré Bioscience receives $908,000 NIH award for preterm birth program By Investing.com - Investing.com Nigeria
Daré Bioscience receives $908,000 NIH award for preterm birth program - Investing.com
Daré Bioscience Announces New NIH Funding Award for Approximately $908,000 to Advance DARE-PTB2 for the Prevention of Preterm Birth - Barchart.com
Lind Global’s capped stake in Dare Bioscience (NASDAQ: DARE) tops key ownership threshold - Stock Titan
Daré Bioscience CEO, Sabrina Martucci Johnson, Participates in the Virtual Investor “Why Now” On-Demand Series - Barchart.com
IPO Databook: Daré Bioscience (DARE US)Aug 2026 - Smartkarma
Daré Bioscience publishes sildenafil cream study results - Investing.com
Daré Bioscience’s Sildenafil Cream Data in Postmenopausal Women Published in MenopauseThe Journal of The Menopause Society - Barchart.com
A sildenafil cream study in 21 women after menopause found all doses well tolerated - Stock Titan
A women’s health biotech launches one product while preparing another to generate revenue - Stock Titan
L1 Capital caps Dare Bioscience (DARE) stake at 9.99% - Stock Titan
Drugmakers still struggling to keep up with spiking estrogen patch demand - AOL.com
Daré Bioscience (DARE) Q2 2026 Earnings Call Transcript - AOL.com
Dare Bioscience (NASDAQ: DARE) sets up $12.4M in potential warrant cash - Stock Titan
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List - sahmcapital.com
Forbes puts a women's health biotech CEO on its 2026 innovation list - Stock Titan
Dare Bioscience Inc (DARE) (Q2 2026) Earnings Call Highlights: C - GuruFocus
Dare Bioscience Prices $6.0 Million Registered Direct Offering - Minichart
Form 8K Dare Bioscience Inc For: 17 August By Investing.com - Investing.com Nigeria
Daré Bioscience Raises ~$6 Million in Equity Offering at $1.37 With Attached Warrants - TradingView
H.C. Wainwright reiterates Dare Bioscience stock rating at buy By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
Q2 2026 Dare Bioscience Inc Earnings Call Transcript - GuruFocus
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Daré Bioscience raises $6M in registered direct offering By Investing.com - Investing.com India
Dare Bioscience Prices $6 Million Registered Direct Offering; Shares Fall - marketscreener.com
Daré Bioscience raises $6M in registered direct offering - Investing.com
Daré Bioscience Announces $6.0 Million Registered Direct Offering and Concurrent Private Placement - moomoo.com
Daré Bioscience Announces Pricing of $6.0 Million - GlobeNewswire
Daré Bioscience, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Dare Bioscience earnings beat by $0.11, revenue topped estimates - Investing.com Canada
Daré Bioscience (DARE) Launches New Product Amid Challenging Val - GuruFocus
Dare Bioscience (DARE) Q2 Results Highlight Challenges Amid Low Valuation on Price-to-Sales Basis - GuruFocus
Daré Bioscience launches Flora Sync LF5 for direct revenue - scanx.trade
Earnings call transcript: Daré Bioscience Q2 2026 loss narrows as stock jumps after hours - Investing.com
Dare Bioscience Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Dare Bioscience, Inc. (DARE) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Dare Bioscience Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Dare Bioscience Q2 net loss narrows as revenue rises, R&D expenses decline - TradingView
Dare Bioscience Q2 Results: Net loss narrows to $3.0M, cash falls - scanx.trade
Dare Bioscience, Inc. 2026: Revenue $187.55K, EPS ($0.2) — 10-Q Summary - TradingView
Daré Bioscience Reports Second Quarter 2026 Results and Highlights Commercial Inflection as Multi-Product Women’s Health Strategy Advances - The Manila Times
Daré Bioscience launches Flora Sync, its first directly commercialized product - Stock Titan
Dare Bioscience reports Q2 2026: $0.19M revenue, $2.98M net loss, cash $12.6M - TradingView
Dare Bioscience Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Transcript : Daré Bioscience, Inc.Special Call - marketscreener.com
Women keep recommending £20 gynaecologist-backed dryness buy that sold out 5 times - AOL.co.uk
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):